Neumora Therapeutics Inc. Company Profile
NASDAQ: NMRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Neumora Therapeutics at a glance
Neumora Therapeutics Inc. (NASDAQ: NMRA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Watertown, MA. Neumora Therapeutics is led by Dr. Joshua Pinto Ph.D. and employs about 63 people. The company's shares have traded publicly since 2023.
At a market capitalization of $63.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001885522, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Neumora Therapeutics do?
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Neumora Therapeutics Inc.
- Ticker
- NASDAQ: NMRA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Joshua Pinto Ph.D.
- Employees
- 63
- Headquarters
- 260 Arsenal Place, Watertown, MA, United States
- Phone
- 857 760 0900
- Website
- neumoratx.com
- IPO year
- 2023
- Market cap
- $63.01M
- SEC CIK
- 0001885522
- Latest annual report
- 10-K · Mar 30, 2026
Companies similar to Neumora Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs NMRA |
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs NMRA |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs NMRA |
| CRDFCardiff Oncology Inc. | 0.8528 | -4.46% | $66.34M | vs NMRA |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs NMRA |
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs NMRA |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs NMRA |
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs NMRA |